+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and symptom improvement of ALKS 7290 tablets compared with placebo in adults diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This phase 2, randomized, double-blind study aims to understand how ALKS 7290 affects ADHD symptoms over a four-week period. The study involves adult participants aged 18 to 65 who meet specific diagnostic criteria and have moderate or worse symptom severity. Participants will take ALKS 7290 tablets or placebo capsules daily by mouth for 4 weeks. The trial includes multiple dose levels of ALKS 7290 alongside a placebo group, with treatment effects compared across these groups. The study is designed with a parallel group model and triple blinding to ensure unbiased assessment. Throughout the study, participants will be regularly evaluated for changes in their ADHD symptoms using the Attention Deficit Disorder Investigator Symptom Rating Scale AISRS and the Clinical Global Impression-Severity scale. Safety is monitored by tracking adverse events up to six weeks. Participant health, medication stability, and symptom severity are assessed before and during the trial to measure treatment impact and ensure well-being.

Age: 18Years - 65YearsAll GendersPhase 2
28 locations